Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Sufentanil and chronic postsurgical pain in non-major scheduled abdominal surgery
2023-510140-21-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sufentanil in Persistent postsurgical pain (PPSP), sponsored by CHU Amiens-Picardie. Primary endpoint: Incidence of chronic postsurgical pain at 3 months. Planned start Mar 2024; status: authorised.
02
Drugs
sufentanil
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on 2023-510140-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510140-21-00.